





Jeffrey Dunn, MD

Clinical Professor, Neurology & Neurological Sciences

 NIH Biosketch available Online

 Curriculum Vitae available Online

CLINICAL OFFICES

- **Stanford Neuroscience Health Center**

213 Quarry Rd Rm 2851

MC 5957

Palo Alto, CA 94304

Tel (650) 736-4310

Fax (650) 725-7459

ACADEMIC CONTACT INFORMATION

- **Administrative Contact**

Amy Singh - Administrative Associate

Tel 650.736.4310

Bio

BIO

Jeffrey Dunn, MD, FAAN is Professor of Clinical Neurology and Division Chief of Clinical Neuroimmunology in the Department of Neurology and Neurosciences at Stanford University. His clinical focus is the care of men and women with Multiple Sclerosis, Neuromyelitis Optica, and other conditions in which the immune system disrupts the central nervous system to cause disease. His research employs a collaborative approach to identify biomarkers of disease status and potential therapeutic targets via translational research for novel drug development. Dr. Dunn has served as Principal Investigator in more than 20 clinical trials of new and emerging treatments for MS. Dr. Dunn is dedicated to medical education, serving as the Neurology Clerkship Director for the Stanford University School of Medicine, and as Fellowship Director for the Clinical Neuroimmunology Fellowship Program that seeks to train the next generation of leaders in Multiple Sclerosis. Dr. Dunn is an elected Fellow of the American Academy of Neurology. He has been awarded the prestigious Henry J. Kaiser Family Foundation Award for Excellence in Clinical Teaching, the Arthur Bloomfield Award in recognition of excellence in the teaching of clinical medicine, and the Lysia Forno Award for teaching excellence.

CLINICAL FOCUS

- Multiple Sclerosis
- Neuromyelitis Optica
- Transverse Myelitis
- Neurology

ACADEMIC APPOINTMENTS

- Clinical Professor, Neurology & Neurological Sciences

ADMINISTRATIVE APPOINTMENTS

- Chief, Division of Neuroimmunology, Department of Neurology & Neurological Sciences, (2009- present)
- Chair, Multiple Sclerosis Section; American Academy of Neurology, (2018-2020)
- Neurology Clerkship Director, Stanford University School of Medicine, (2008-2019)
- Board Member, National Medical Advisory Committee, National Multiple Sclerosis Society, (2018- present)

- Fellowship Director, Clinical Neuroimmunology Fellowship Program; Stanford University, (2010-2017)

HONORS AND AWARDS

- A. B. Baker National Teacher of the Year Recognition Award, American Academy of Neurology (2019)
- Healthcare Partner of the Year, National Multiple Sclerosis Society, NorCal (2019)
- Arthur L. Bloomfield Award in Recognition of Excellence in Teaching Clinical Medicine, Stanford University School of Medicine (2017)
- Henry J. Kaiser Family Foundation Award for Excellence in Clinical Teaching, Stanford University School of Medicine (2013)
- AUPN Neurology national recruitment award, Association of University Professors of Neurology (2012)
- Excellence in Teaching Award, Stanford University School of Medicine (2011-2012)
- AUPN Neurology Recruitment Award (highest percentage in U.S.), Association of University Professors of Neurology (2011)
- Arthur L. Bloomfield Award in Recognition of Excellence in the Teaching of Clinical Medicine, Stanford University School of Medicine (2011)
- Excellence in Teaching Award, Stanford University School of Medicine (2010-2011)
- Excellence in Teaching Award, Stanford University School of Medicine (2009-2010)
- Fellow, American Academy of Neurology (2008-present)
- Lysia K. Forno Award for Excellence in Teaching Neurology Residents, Stanford University Department of Neurology & Neurosciences (2008-2009)
- Excellence in Neurology Clerkship Teaching Award, Stanford University Department of Neurology & Neurosciences (2008,2009,2010,2011,2012,2013,2014,2015,2016,2017)
- "America's Top Rated Physicians", Guide to Top Doctors (1998-2007, 2010-2019)

BOARDS, ADVISORY COMMITTEES, PROFESSIONAL ORGANIZATIONS

- Fellow, American Academy of Neurology (2007 - present)
- Member, Association of University Professors of Neurology (2010 - present)
- Member, Consortium of MS Centers (2008 - present)
- Member, Accelerated Cure Project (2010 - present)
- Member, San Francisco Neurological Society (2009 - present)

PROFESSIONAL EDUCATION

- Residency: University of Washington Medical Center (1993) WA
- Board Certification: Neurology, American Board of Psychiatry and Neurology (1994)
- Medical Education: Temple University School of Medicine (1989) PA
- Residency, University of Washington , Neurology (1993)
- M.D., Temple University , Medicine (1989)
- B.A., Haverford College , French Literature (1983)

COMMUNITY AND INTERNATIONAL WORK

- Editorial Board
- PACTRIMS Member

LINKS

- <http://neurology.stanford.edu>: <http://neurology.stanford.edu>
- Video Story: <https://stanfordhealthcare.org/stanford-health-care-now/why-i-got-into-medicine/why-medicine-jeffrey-dunn-md.html>
- Get a Second Opinion: <https://stanfordhealthcare.org/second-opinion/overview.html>

Research & Scholarship

CURRENT RESEARCH AND SCHOLARLY INTERESTS

Translational research in the human application of emerging immunotherapies for neurological disease, focusing on Multiple Sclerosis, CIS, transverse myelitis and Neuromyelitis Optica (NMO). Collaborative research with Stanford and extramural scientific faculty to identify biomarkers of disease activity and treatment response in humans. Clinical trials to assess efficacy of emerging treatments for MS, CIS and NMO.

CLINICAL TRIALS

- Vitamin D Supplementation in Multiple Sclerosis, Recruiting
- A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis, Not Recruiting
- An Extension Protocol for Multiple Sclerosis Patients Who Participated in Genzyme-Sponsored Studies of Alemtuzumab, Not Recruiting
- Clinical Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Ponesimod in Patients With Relapsing-remitting Multiple Sclerosis, Not Recruiting
- Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study Two, Not Recruiting

Teaching

STANFORD ADVISEES

Postdoctoral Faculty Sponsor

Nina Bozinov

Publications

PUBLICATIONS

- **The North American Registry for Care and Research in Multiple Sclerosis**
Rammohan, K. W., Li, D., Halper, J., Murphy, S., Patton, L., Berger, J., Carlson, A. M., Chinae, A., Cohan, S., Cross, A. H., Dunn, J., Fox, E. J., Gupta, et al
SAGE PUBLICATIONS LTD.2019: 79–80
- **Infectious Complications of Multiple Sclerosis Therapies: Implications for Screening, Prophylaxis, and Management** *OPEN FORUM INFECTIOUS DISEASES*
Epstein, D. J., Dunn, J., Deresinski, S.
2018; 5 (8)
- **Autoimmune Hepatitis During Treatment of Multiple Sclerosis with Alemtuzumab**
Carlson, A., Bozinov, N., Kipp, L., Dunn, J., Lock, C.
LIPPINCOTT WILLIAMS & WILKINS.2018
- **Ocrelizumab versus Interferon beta 1a in Relapsing Multiple Sclerosis** *New England Journal of Medicine*
Hauser, S. L., OPERA Clinical Investigators , et al
2017; 376 (3): 221-234
- **Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients.** *Neurology*
Giovannoni, G., Cohen, J. A., Coles, A. J., Hartung, H. P., Havrdova, E., Selmaj, K. W., Margolin, D. H., Lake, S. L., Kaup, S. M., Panzara, M. A., Compston, D. A.
2016; 87 (19): 1985–92
- **IFN-β Treatment Requires B Cells for Efficacy in Neuroautoimmunity.** *Journal of immunology*
Schubert, R. D., Hu, Y., Kumar, G., Szeto, S., Abraham, P., Winderl, J., Guthridge, J. M., Pardo, G., Dunn, J., Steinman, L., Axtell, R. C.
2015; 194 (5): 2110-2116
- **MRI CHARACTERISTICS OF CNS DEMYELINATING DISEASE IN ETHNIC INDIAN PATIENTS**
Hua, L. H., Lee, J., Dorfman, L., Dunn, J.
SAGE PUBLICATIONS LTD.2014: 920

- **Disease-modifying therapies for nonrelapsing multiple sclerosis: Absence of evidence does not constitute evidence of absence.** *Neurology. Clinical practice*
Dunn, J.
2013; 3 (6): 515–18
- **Analysis of B Cell Subsets in Multiple Sclerosis Patients on Immunomodulatory Therapy Reveals Modulation of CD19+CD24hiCD38hi Cells with Implications for the Diagnosis and Monitoring of MS**
Schubert, R., Goodyear, A., Abraham, P., Dunn, C., Steinman, L., Dunn, J., Axtell, R.
LIPPINCOTT WILLIAMS & WILKINS.2013
- **Randomized study combining interferon and glatiramer acetate in Multiple Sclerosis** *Annals of Neurology*
Lublin, F., CombiRx Investigators
2013; 73 (3): 327-340
- **Mobility Concerns in Multiple Sclerosis** *US Neurology*
Lee, J., Dunn, J.
2013; 9 (1): 17-23
- **Disease modifying therapies for non relapsing Multiple Sclerosis** *Neurol Clin Pract*
Dunn, J.
2013; December (3): 515-518
- **Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial** *LANCET*
Coles, A. J., Twyman, C. L., Arnold, D. L., Cohen, J. A., Confavreux, C., Fox, E. J., Hartung, H., Havrdova, E., Selmaj, K. W., Weiner, H. L., Miller, T., Fisher, E., Sandbrink, et al
2012; 380 (9856): 1829-1839
- **Protective effect of an elastase inhibitor in a neuromyelitis optica-like disease driven by a peptide of myelin oligodendroglial glycoprotein** *MULTIPLE SCLEROSIS JOURNAL*
Herges, K., de Jong, B. A., Kolkowitz, I., Dunn, C., Mandelbaum, G., Ko, R. M., Maini, A., Han, M. H., Killestein, J., Polman, C., Goodyear, A. L., Dunn, J., Steinman, et al
2012; 18 (4): 398-408
- **Protective Effect of elastase inhibitor in a neuromyelitis optica-like disease driven by a peptide of myelin oligodendrocyte glycoprotein** *Multiple Sclerosis*
Herges K, DeJong BA, Kolkowitz I, Dunn C, Mandelbaum G, Maini A, Han M, Killestein J, Polman C, Goodyear A, Dunn J, Steinman L, Axtell RC
2012; 18 (4): 398-408
- **Alemtuzumab for patients with relapsing Multiple Sclerosis after disease modifying therapy: a randomized controlled Phase 3 trial.** *Lancet*
A, C. J., CARE MS II, I.
2012; Nov 24 (380): 1829-1839
- **Dalfampridine: a brief review of its mechanism of action and efficacy as a treatment to improve walking in patients with multiple sclerosis** *CURRENT MEDICAL RESEARCH AND OPINION*
Dunn, J., Blight, A.
2011; 27 (7): 1415-1423
- **Dalfampridine: A brief review of its Mechanism of Action and Efficacy as a treatment to improve walking in patients with Multiple Sclerosis** *Current Research Medical Opinion*
Dunn J, Blight A
2011; 27 (7): 1415-1423
- **Impact of mobility impairment on the burden of caregiving in individuals with multiple sclerosis** *EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH*
Dunn, J.
2010; 10 (4): 433-440
- **Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta** *LANCET NEUROLOGY*
Wynn, D., Kaufman, M., Montalban, X., Vollmer, T., Simon, J., Elkins, J., O'Neill, G., Neyer, L., Sheridan, J., Wang, C., Fong, A., Rose, J. W.
2010; 9 (4): 381-390
- **The impact of mobility impairment on the burden of caregiving in individuals with multiple sclerosis** *Expert Rev. Pharmacoeconomics Outcomes Res.*

- Dunn, J.
2010; 10 (4): 433-440
- **Cytomegalovirus Infection with MRI Signal Abnormalities Affecting the Optic Nerves, Optic Chiasm, and Optic Tracts** *JOURNAL OF NEURO-OPHTHALMOLOGY*
Pershing S., Dunn, J., Khan, A., Liao, Y. J.
2009; 29 (3): 223-226
 - **CMV Optic Neuritis with Extensive Tracking along the Visual Pathway** *J Neuro-Ophthalmology*
Pershing S, D. K.
2009; 29 (3): 223-226
 - **Glatiramer Acetate after Induction Therapy with Mitoxantrone in Relapsing Multiple Sclerosis** *Multiple Sclerosis*
Vollmer T, P. B.
2008; Apr 18
 - **Tovaxin for Early Relapsing Multiple Sclerosis Phase 2b Placebo Controlled Trial of Autologous T cell vaccination in patients with CIS or RRMS** *Multiple Sclerosis*
Fox, E., The TERMS Study Investigators
2008; 14: S5-S27
 - **Glatiramer Acetate after Mitoxantrone Induction improves MRI markers of lesion volume and permanent tissue injury in MS** *J Neurol*
Arnold D., Campagnolo D., Panitch H., Bar-Or A., Dunn J, Freedman M., Gazda S.K., Vollmer T.
2008; 255: 1473-1478
 - **Daclizumab in Patients with Active Relapsing Multiple Sclerosis on Concurrent Interferon beta Therapy; Week 24 data Phase II** *ECTRIMS*
Montalban X, K. W.
2007; 10/11/07: S18
 - **Randomized, Double Blind, Dose Comparison Study of Glatiramer Acetate in Relapsing Remitting MS** *Neurology*
Cohen JA, R. G.
2007; 68 (12): 939-944
 - **Safety and Tolerability of Glatiramer Acetate in Pediatric Patients with Relapsing Remitting Multiple Sclerosis** *ECTRIMS/ACTRIMS*
Krupp L, Banwell B, Picone M, Dunn J, Weinstock-Guttman B, Pardo L.
2005: abstract
 - **Comprehensive Outpatient Management of Patients with Multiple Sclerosis** *RIMS MS Symposium*
Odderson I, D.
2001: abstract
 - **Novantrone in the Treatment of Multiple Sclerosis** *Alliance News*
Dunn Jeffrey, Kita M., Lucas S., Bowen J.,
2001: 1-3
 - **Clinical Advisory Committee Statement** *Health Care Connection*
Bowen J., Dunn Jeffrey E., Kraft G.H., Ratley G., Shilling J., Smith C., Thompson L.
1999; I (1): 1-2
 - **Gingko Biloba in the Treatment of Alzheimer's Disease** *Alternative Medicine*
Dunn Jeffrey E., Maidan R., Pallis J.
1998; 1 (15): 1-2
 - **Atherosclerotic Aortic Disease as a Source of Embolic Infarct** *Journal of Neurovascular Disease*
Bursell John P., Odderson I., Dunn Jeffrey E.
1996; 1 (2): 35-38
 - **INTRACEREBRAL BACILLARY ANGIOMATOSIS IN A PATIENT INFECTED WITH HUMAN-IMMUNODEFICIENCY-VIRUS** *ANNALS OF INTERNAL MEDICINE*
Spach, D. H., Panther, L. A., Thorning, D. R., Dunn, J. E., Plorde, J. J., MILLER, R. A.
1992; 116 (9): 740-742

- **Intracerebral Bacillary Angiomatosis in a Patient Infected with HIV** *Annals of Internal Medicine*
Spach, D., Panther L., Thorning D., Dunn Jeffrey E., Plorde J.L., Miller, R.
1992; 116: 740-743

PRESENTATIONS

- The Utility of Magnetic Resonance Imaging in Multiple Sclerosis - Pan-Asian Committee for Treatment & Research in MS (11/6/2014)
- An Approach to Transverse Myelitis - Stanford University (10/31/2014)
- Treatment Decisions at the intersection of trials and practice - 6th AnnualECTRIMS-ACRIMS (9/12/2014)
- Is Multiple Sclerosis not one disease but several? - Cleveland Clinic Foundation (6/27/2014)
- Multiple Sclerosis Highlights in the Field - American Academy of Neurology (4/30/2014)